Evidence map›Paper›PMID 30866863›Full record

ArticleBMC cancer2019

8-bromo-7-methoxychrysin suppress stemness of SMMC-7721 cells induced by co-culture of liver cancer stem-like cells with hepatic stellate cells.

Qi Wen, Chang Xu, Jie Zhou, Nuo-Min Liu, Ying-Hong Cui, Mei-Fang Quan, Jian-Guo Cao, Kai-Qun Ren

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qi WenDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China.
Chang XuDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China.
Jie ZhouDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China.
Nuo-Min LiuDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China.
Ying-Hong CuiDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China.
Mei-Fang QuanDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China.
Jian-Guo CaoDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China. caojianguo2005@126.com.
Kai-Qun RenDepartment of Pharmaceutical Science, Medical College, Hunan Normal University, Changsha, 410013, China. kaiqunren@126.com.
Hunan Normal University · CNHunan University of Traditional Chinese Medicine · CN

Funding

The National Natural Science Fund 3150913The National Natural Science Fund 81172375the Provincial Training Program of Innovation and Entrepreneurship for Undergraduates. 201610542037
6 · The paper itself

Abstract

backgroundOur previous works have demonstrated that 8-bromo-7-methoxychrysin suppressed stemness of human hepatocellular carcinoma (HCC) cell line SMMC-7721 induced by condition medium from hepatic stellate cell line LX-2 that was activated by liver cancer stem-like cells (LCSCs). However, whether and whereby BrMC inhibits the stemness induced by co-culture of LCSCs and LX-2 cells remains to be investigated.

methodsThe second-generation spheres by sphere culture were identified and used as SMMC-7721-and MHCC97H-derived LCSLCs. SMMC-7721-and MHCC97-derived LCSCs/LX-2 cells transwell co-culture system was treated with BrMC and its lead compound chrysin. The concentrations of IL-6, IL-8, HGF and PDGF in condition medium from co-culture were measured by enzyme-linked immunosorbent assay (ELISA). The stemness of SMMC-7721 cells was evaluated by sphere formation assay and western blot analysis for expression levels of cancer stem cell markers (CD133 and CD44).The expression levels of cancer-associated fibroblast markers (FAP-α and α-SMA) were employed to evaluate pathologic activation of LX-2 cells. Addition of IL-6 and/or HGF or deletion of IL-6 and/or HGF was conducted to investigate the mechanisms for BrMC and chrysin treatment in SMMC-7721-derived LCSLCs co-cultured with LX-2cells.

resultsThe co-culture of LCSLCs with LX-2 cells increased sphere formation capability as well as expression of CD133 and CD44 in SMMC-7721 cells, meanwhile, upregulated expression of FAP-α in LX-2 cells. ELISA indicated that the concentrations of IL-6 and HGF were significantly elevated in Co-CM than that of condition media from co-cultured SMMC-7721 cells/LX-2 cells. Treatment of BrMC and chrysin with co-cultures of SMMC-7721- and MHCC97H-derived LCSLCs and LX-2 cells effectively inhibited the above responses. Moreover, addition of IL-6 and/or HGF induced stemness of SMMC-7721 cells and activation of LX-2 cells, conversely, deletion of IL-6 and/or HGF suppressed those. Furthermore, the inhibitory effects of BrMC and chrysin on stemness of SMMC-7721 cells and activation of LX-2 cells were attenuated by addition of IL-6 or HGF, and enhanced by deletion of IL-6 or HGF.

conclusionsOur results suggest IL-6 and HGF may be the key communication molecules for the interaction between LCSLCs and HSCs, and BrMC and chrysin could block these effects and be the novel therapeutic candidates for HCC management.

Indexed as

AnimalsCarcinoma, HepatocellularCell Line, TumorCoculture TechniquesDose-Response Relationship, DrugFemaleFlavonoidsHepatic Stellate CellsHumansInterleukin-6Interleukin-6 InhibitorsInterleukin-8Liver NeoplasmsMiceMice, Inbred BALB CMice, Nude8-bromo-7-methoxychrysinFlavonoidsIL6 protein, humanInterleukin-6Interleukin-6 InhibitorsInterleukin-88-bromo-7-methoxychrysinChrysinHepatocellular carcinoma, liver cancer stem cellHepatocyte growth factorInterleukin 6

Identifiers

PMID30866863
PMCPMC6416872
OpenAlexW2921406060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.